Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Live is Caixin Global's real-time news portal, featuring 24-hour breaking news, short-form analysis, and roundups from business and social media in China.

TRENDING
Huawei Eyes Fashion-Conscious Consumers With Smart Sunglasses Release
Investors Lukewarm on BYD’s Success, Unfazed by Geely Slump
China’s First Cloned Pet Cat Was Born in July, Biotech Company Announces
LATEST
Court Rules Baidu Responsible for ‘Defamatory’ Content Published by User
Huawei Releases ‘World’s Most Powerful’ AI Processor
Shanghai’s New Tech Board Sees High Valuations in First Month
Luckin: A Starbucks or an Amazon?
Datang Telecom Reports 49% Revenue Drop in First Half
Tianqi Lithium Stock Down 2% After Damning H1 Report
R&F Properties Ends EV Partnership With Hawtai Motor
China Telecom Backs 5G Network-Sharing With Rivals
No 4G Network Slowing to Give Way to 5G, Ministry Says
Ikea to Invest $1.4 Billion in China With Focus on E-Commerce
Is This the End of Gas-Fueled Cars in China?
China’s Slowing Industrial-Robot Sector to See ‘Significant’ Change, Official Warns
Gaming Platform Steam to Launch China-Specific Version
Spat Grows Between Internet Security-Firm Bigwigs
Moderate Ozone Pollution to Plague China’s West
Investors Lukewarm on BYD’s Success, Unfazed by Geely Slump
Focus Media Profit Plummets, But Investors Don’t Mind
Apple May Turn to China’s BOE for Advanced Phone Screens
Pinduoduo Shares Surge 15% as 2Q Results Beat Estimates
Huawei Eyes Fashion-Conscious Consumers With Smart Sunglasses Release
Regulator Finds Kangmei Pharma Fabricated Financial Reports

By Wang Juanjuan and Denise Jia / May 18, 2019 05:08 AM / Finance

Photo: IC Photo

Photo: IC Photo

China’s securities regulator concluded an investigation of one of China’s largest listed drugmakers, finding the company fabricating its financial reports from 2016 to 2018.

Shanghai-listed traditional Chinese medicine supplier Kangmei Pharmaceutical Co. Ltd. used fake bank deposit slips to inflate its cash reserves, forged documents for non-existent business activities, and transferred company funds to related parties to trade in its own stock, the China Securities Regulatory Commission (CSRC) said Friday.

Kangmei’s auditor, GP Certified Public Accountants Co. Ltd., the largest auditing company in Guangdong, was also put under investigation for failure to perform due diligence.

Kangmei disclosed April 30 that it was targeted by regulators on suspicion of false financial reports involving a 29.9 billion yuan ($4.4 billion) overstatement of cash on hand.

But the company’s founder and chairman Ma Xingtian described the overstatement as an “accounting error” as results of loopholes in internal controls and financial management. After correcting the accounts, the company’s net profit in 2016 and 2017 would have been reduced by half.

Kangmei was previously involved in several bribery cases involving government officials. According to court documents released last June, the company bribed Cai Ming, former director of the drug safety supervision department at the Guangdong Province Food and Drug Administration, to the tune of 300,000 yuan from 2014 to 2015.

In February, the company was rattled by default risks on $300 million of bonds. The crisis was eased later after the Guangdong provincial government stepped in.

Share this article
Open WeChat and scan the QR code
Copyright © 2019 Caixin Global Limited. All Rights Reserved.